J.P. Morgan analyst Chris Schott has maintained their bullish stance on REGN stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chris Schott has given his Buy rating due to a combination of factors that highlight the positive trajectory of Regeneron’s stock. The recent approval of Eylea HD for RVO and Q4W dosing is seen as a significant milestone, enhancing the product’s market potential. This development is expected to drive growth as physicians have shown a preference for having Q4W on the label before transitioning patients, and RVO constitutes a substantial portion of the market.
Moreover, Schott is optimistic about Regeneron’s broader outlook, particularly with upcoming catalysts such as the LAG3 readout. Despite recent challenges, the company’s strong portfolio, including Dupixent and Eylea, along with its cash reserves, support its current valuation. Anticipated approvals and data releases in the near future are expected to further bolster the stock’s performance, reinforcing the Buy recommendation.
In another report released yesterday, Bernstein also assigned a Buy rating to the stock with a $818.00 price target.
REGN’s price has also changed moderately for the past six months – from $596.540 to $702.750, which is a 17.80% increase.